|
Mar 3
|
Asian Stocks to Decline as Tariffs Spark US Rout: Markets Wrap
|
|
Mar 3
|
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
|
|
Mar 3
|
Sector Update: Health Care Stocks Advance Late Afternoon
|
|
Mar 3
|
AbbVie enters obesity treatment via Gubra licensing agreement
|
|
Mar 3
|
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
|
|
Mar 3
|
AbbVie, Reddit, Allegro MicroSystems: Market Minute
|
|
Mar 3
|
AbbVie Enters Obesity Market Through Licensing Deal With Denmark's Gubra
|
|
Mar 3
|
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
|
|
Mar 3
|
AbbVie enters obesity space with $2.3bn Gubra deal
|
|
Mar 3
|
AbbVie gets into obesity with $350M deal for once-weekly shot
|
|
Mar 3
|
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
|
|
Mar 2
|
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now?
|
|
Mar 2
|
Insiders At AbbVie Sold US$23m In Stock, Alluding To Potential Weakness
|
|
Mar 1
|
AbbVie Inc. (ABBV): Among the Best Psychedelic Stocks to Buy in 2025
|
|
Feb 28
|
AbbVie's Next Big Moneymaker? This Drug Just Took a Huge Step Toward Approval
|
|
Feb 28
|
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
|
|
Feb 28
|
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
|
|
Feb 28
|
Drug Stocks Are the New Safe Bet in a Shaky Market
|
|
Feb 28
|
3 Reasons ABBV is Risky and 1 Stock to Buy Instead
|
|
Feb 28
|
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
|